A MULTICENTER RETROSPECTIVE COHORT STUDY INVESTIGATING IMMUNE-RELATED THYROID TOXICITY IN ADJUVANT MELANOMA PATIENTS TREATED WITH A PD-1 INHIBITOR

Introduction

- Immune checkpoint inhibitor (ICI) related thyroiditis (irTAE) is a common adverse reaction
- IrTAEs are observed more frequently after PD-1 inhibitors compared to CTLA-4 inhibitors
- PD-1 inhibitors are used in the adjuvant setting after resection of melanoma
- IrTAE is frequently resulting in lifelong hormone replacement therapy
- The real-world incidence, clinical timeline characteristics, and associated factors in the adjuvant setting are unexplored

Objectives

• In a national cohort of adjuvant melanoma patients treated with a PD-1 inhibitor, to

- describe the incidence of irTAEs
- describe the clinical timeline characteristics of the transient and persistent irTAEs
- test if age and sex were associated with the risk of developing irTAE
- investigate associations between irTAE with recurrencefree survival (RFS) and overall survival (OS)

Methods

- Melanoma patients receiving first cycle of adjuvant PD-1 inhibitor between Nov 2018 and Dec 2020
- Demographics, treatment characteristics, laboratory findings and FDG-PET/CT scan results were extracted from the Danish Metastatic Melanoma Database
- Data cut off March 2022
- Key exclusion criteria: known thyroid illness, ir-hypophysitis, fewer than two reported TSH values, no baseline TSH value

Results

- Of 554 adjuvant melanoma patients 454 passed the exclusion criteria • 56.6% were men and 43.4% were women
- Patients with irTAE had a median age of 59.9 years (17.6-86.1) and without irTAE 62.2 years (21.1-86.3)
- persistent
- Age per 10 years increase was significantly associated with a lower risk of developing irTAEs (HR 0.86; 95% CI 0.75 - 0.98; p = 0.024)

Time to irTAE (days) (range)

Levothyroxine treatm

Time to start levothy first abnormal TSH v median (IQR)

Duration of irTAE* ((IQR)


Time to hyperthyroid median (range)


Time to hypothyroid (range)

The phases of the irT. Hyperthyroid+hyp Hypothyroid+hype Isolated hyperthyro Isolated hypothyroi

Definitions of irTAE

- IR 0-3 months:2.7/1,000 pers-day
- IR 3-6 months: 0.5/1,000 pers-day






Conclusion

• 99 developed irTAEs (21.8%), of these were 46.5% transient and 53.5%

• The table compares clinical timeline characteristics between transient and persistent irTAE

	All i		
	Transient irTAE N=46	PersistentirTAE N=53	p-value
s), median			
,,	55 (13-280)	44 (19-427)	0.57
ment, n (%)	0 (0%)	53 (100%)	
yroxine after			
value (days),		57 (29-63)	
		57 (29-03)	
(days), median	84 (57-140)		
id (days),			
	53 (13-280)	28 (19-349)	0.16
d (days), median			
· · //	109 (26-336)	84 (36-447)	0.48
ГАЕ n (%)			
pothyroid	6(13)	39 (73.6)	<0.001
perthyroid	0(0)	1 (1.9)	
roid	29 (63)	2 (3.8)	<0.001
oid	11 (24)	11 (20.7)	0.81

- Transient: ≥ two consecutive abnormal TSH values *not requiring* hormone replacement Persistent: ≥ two consecutive abnormal TSH values *requiring* hormone replacement



• No significant association between irTAE and RFS (HR 0.86; 95% CI 0.50 - 1.48; p = 0.587), or OS (HR 1.05; 95% CI 0.52 - 2.12, p = 0.589)

• IrTAE is a common side-effect to adjuvant PD-1 inhibitors primarily occurring within the first three months, with different degrees of severity • Female sex and younger age are predictors for developing irTAEs • IrTAE was not associated with better clinical outcome measurements • Future prospective studies are needed to understand additional predictors and competing risk factors in the adjuvant setting of melanoma patients